[PDF] Top 20 España y la Unión Europea: una relación cambiante
Has 10000 "España y la Unión Europea: una relación cambiante" found on our website. Below are the top 20 most common "España y la Unión Europea: una relación cambiante".
Analysis of Expression Of SIRT1 Gene In Patients With Chronic Myeloid Leukemia Resistant To Imatinib Mesylate
... 10. Lau A, Seiter K, Deitcher OR, Glaspy J, Gonzalez R, Sato T, et al. 179 Prognostic Assessment and Treatment of Primary Gastric Lymphomas: How Endoscopic Ultrasonography Can Help in Tailoring Patient Management ... See full document
224
MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia
... reduced expression of MLL2/KMT2D in breast cancer [11] and a decreased expression of MLL3/KMT2C in larynx car- cinoma samples when compared to normal adjacent tissue from the same patients, with the ... See full document
335
Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor
... often patients on imatinib develop resistance, and the identification of resistance should trigger muta- tional analysis of BCR-ABL1 kinase ...managing imatinib resistance have been published ... See full document
8
Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib
... decreased expression of this gene, resulting in high plasma bilirubin levels that form the basis for Gilbert’s syndrome ...cer patients administered irinotecan. Haplotype analysis showed that ... See full document
11
Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose
... therapy, imatinib dose escalation was one of very few available options in patients with CML-CP resistant to stan- dard dose imatinib (400 mg ...of imatinib resistance that could be ... See full document
53
Case Report Severe peripheral arterial occlusive disease in chronic myeloid leukemia patient during nilotinib therapy: report of a case and review of literature
... some patients needed repeated PTA and stent implantation, some even ...identifies patients exposed to high risk of atherosclerotic events during nilotinib ...therapy. Patients with multiple risk ... See full document
9
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib resistant chronic myeloid leukemia cells
... and/or imatinib were evaluated by MTT ...and imatinib‑resistant KBM5‑T315I CML cell ...with imatinib, demonstrating that celecoxib could strengthen the cytotoxicity of imatinib in ... See full document
15
The role of dasatinib in the management of chronic myeloid leukemia
... for chronic, blastic, or accelerated phase chronic myeloid leukemia (CML) patients who are resistant or intolerant to previous ...in imatinib-resistant or ... See full document
24
Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
... term option in CML, at least for a proportion of patients, and other strategies need to be explored. Many novel compounds are currently being investigated pre-clinically and clinically, and therapeutic approaches ... See full document
8
Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
... kinases, whose tightly controlled physiologic activities become deregulated and con- stitutively active by the juxtaposition of BCR. Additionally, BCR-ABL plays a central role in controlling downstream pathways involved ... See full document
5
Factors affecting the response to tyrosine kinase inhibitors in chronic myeloid leukaemia
... site. Imatinib, an inhibitor of ABL kinase and platelet derived growth factor (PDGF), was one such compound which emerged and was promoted due to its favourable pharmacokinetics and in vitro selectivity against ... See full document
9
Targeted treatment of chronic myeloid leukemia: role of imatinib
... Abstract: Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by clonal expansion of pleuripotent hematopoetic stem ...of imatinib as an accepted targeted therapy in ... See full document
12
Mechanisms of AXL overexpression and function in Imatinib- resistant chronic myeloid leukemia cells
... In the present study, we report compelling evidence that AXL is overexpressed in several TKI-resistant CML cell lines. Importantly, we establish that AXL knockdown using specific siRNA sensitized ... See full document
28
Effects of Purvalanol A on Imatinib-Sensitive and -Insensitive Chronic Myeloid Leukaemia Cell Lines
... Mcl-1 was first identified as an early induction gene expressed during myeloid leukemia cell differentiation (Kozopas et al., 1993). It was found to share amino acid sequence similarities with ... See full document
12
Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations
... for chronic myeloid leukemia has changed significantly over the past 15 years, and as of now, there are five BCR-ABL1 (breakpoint cluster region-Abelson murine leukemia viral oncogene homolog ... See full document
22
<p>Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy</p>
... Subsequently, on July 7, 2018, the patient received an infusion of anti-CD19 CAR-T cells that had been activated ex vivo with anti-CD3/CD28 antibody-coated beads and transduced with a lentiviral vector containing the ... See full document
27
Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?
... European Leukemia Net 2013 guidelines via reverse transcriptase quantitative polymerase chain reaction measurement of the level of BCR-ABL1 transcripts in peripheral ... See full document
5
Cytogenetic Response in Chronic Myeloid Leukaemia Patients Treated with Imatinib Mesylate Homolog Drugs: 6 Year’s Transitional Study
... CML patients in ...between patients who initiated Imatib (group A) 1 (4%) and Glivec in (group C) ...CML patients, who were initiated Glivec, while the cytogenetic response for patients who ... See full document
25
Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
... in chronic phase at the time of progression appeared to do better with second generation TKIs rather than allogeneic stem cell ...tivariable analysis however, second-line therapy was not identifi ed as an ... See full document
20
Response to Imatinib Mesylate in patients with Chronic Myeloid Leukemia.
... 53/54 patients treated with at least 300 mg showed complete hematologic responses ...of patients, which were complete in ...in chronic phase, peak levels at steady state were approximately ... See full document
3
Related subjects